BACKGROUND: Neuroendocrine prostate cancer is rare but lethal.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
It is one of the most common extra pulmonary manifestations of small cell cancer.
CASE PRESENTATION: Here we present a case report of a 53-year-old male who presents with a mixed adenocarcinoma and neuroendocrine prostate tumor on a background of previously normal prostate-specific antigen (PSA). His initial symptoms prior to diagnosis included decreased urine output and acute kidney injury (AKI).
CONCLUSION: Neuroendocrine tumor does not elevate the PSA level and hence is often a late finding with a poor prognosis. Special staining on histopathogy is required to reveal this diagnosis.
Hingorani R, Young J, Alweis R. Are you the author?
Department of Medicine, Reading Health System, West Reading, PA, USA; Jefferson Medical College, Philadelphia, PA, USA.
Reference: J Community Hosp Intern Med Perspect. 2014 Nov 25;4(5):25176.